Navigation Links
Verenium Launches DELTAZYM® GA L-E5 Enzyme for Fuel Ethanol Production

CAMBRIDGE, Mass., Sept. 29 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a pioneer in the development and commercialization of high-performance industrial enzyme solutions, today announced that it will now market and sell DELTAZYM® GA L-E5, a high performance enzyme for the saccharification of liquefied starch in the fuel ethanol production process.  The DELTAZYM® GA L-E5 enzyme has demonstrated high ethanol yields at industrial scale using multiple substrates including corn, milo, barley, wheat and cassava.

"Verenium is pleased to be able to enhance our starch processing product offering with this best-in-class glucoamylase enzyme for fuel ethanol production," said Janet Roemer, Verenium's President and Chief Operating Officer.  "Customers using both Verenium's Fuelzyme® alpha-amylase and DELTAZYM® GA L-E5 have reported increased ethanol yields due to demonstrated synergies between the two enzyme products providing fuel ethanol processing plants with superior cost-performance benefits."

Verenium estimates the addressable global market for DELTAZYM® GA L-E5 for fuel ethanol production to be approximately $200 million annually.

To learn more about the DELTAZYM® GA L-E5 or Fuelzyme® enzymes contact Verenium's Customer Relations at or 1.800.523.2990.

About DELTAZYM® GA L-E5 GlucoamylaseDELTAZYM® GA L-E5 is a high activity glucoamylase designed to provide cost benefits and high ethanol yields in fuel ethanol production.  DELTAZYM® GA L-E5 is used to saccharify liquefied mash from various substrates including corn, milo, barley, wheat and cassava.  When used in combination with Verenium's Fuelzyme® alpha-amylase, fuel ethanol processing plants have seen superior ethanol yields due to the demonstrated synergies between the substrate that the Fuelzyme® product provides and the DELTAZYM® GA L-E5 product's main and side activities.

About VereniumVerenium Corporation is a pioneer in the development and commercialization of high-performance enzymes for use in industrial processes.  Verenium currently sells enzymes developed using its R&D capabilities to industrial customers globally for use in markets including grain and oilseed processing, biofuels, animal health and nutrition and other specialty industrial processes.  Verenium has built a world-class R&D organization renowned for its capabilities in the rapid screening, identification, evolution and bioengineering of novel enzymes that act as catalysts for biochemical reactions.  The company harnesses the power of nature and uses its unique, patented technology to create products that transform industries by maximizing efficiency while improving environmental performance. For more information on Verenium, visit

Forward Looking StatementsStatements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's post-closing lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets and future financial performance, results and objectives, all of which are prospective.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, risks associated with Verenium's technologies, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2009 and any updates contained in its subsequently filed quarterly reports on Form 10-Q.  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.Contacts:Kelly Lindenboom

Sarah CarmodyVice President, Corporate Communications

Manager, Corporate Communications617-674-5335

SOURCE Verenium Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Verenium Appoints Kevin Bracken Vice President of Manufacturing
2. Verenium Announces Proposed Public Offering of Common Stock
3. Verenium 1:12 Reverse Stock Split Takes Effect
4. Verenium Announces Reverse Stock Split to Take Effect September 9
5. BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol
6. Verenium Completes Amendment to 8% Senior Convertible Notes
7. Verenium Announces Organizational Changes
8. Verenium Announces First Commercial Cellulosic Ethanol Project
9. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
10. Verenium Corporation to Speak at the Credit Suisse Alternative Energy Conference
11. Verenium Corporation to Announce Third Quarter 2008 Financial Results
Post Your Comments:
(Date:11/24/2015)... SAN DIEGO , Nov. 24, 2015 Halozyme Therapeutics, ... Jaffray Healthcare Conference in New York on ... Dr. Helen Torley , president and CEO, will provide a ... New York at 1:00 p.m. ET/10:00 a.m. ... communication and investor relations, will provide a corporate overview. --> ...
(Date:11/24/2015)... ... 2015 , ... International Society for Pharmaceutical Engineering (ISPE) closed ... events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference took place in Philadelphia, ... number of attendees in more than a decade. , “The 2015 Annual ...
(Date:11/24/2015)... India , November 24, 2015 ... a new market research report "Oligonucleotide Synthesis Market by ... Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, ... 2020", published by MarketsandMarkets, the market is expected to ... Million in 2015, at a CAGR of 10.1% during ...
(Date:11/24/2015)... Massachusetts , November 24, 2015 SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... , Chief Financial Officer, will participate in the Piper Jaffray 27 ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. ...
Breaking Biology Technology:
(Date:11/17/2015)... , Nov. 17, 2015  Vigilant Solutions announces ... joined its Board of Directors. --> ... after recently retiring from the partnership at TPG Capital, ... companies with over $140 Billion in revenue.  He founded ... across all the TPG companies, from 1997 to 2013.  ...
(Date:11/12/2015)... CAMBRIDGE, Mass. , Nov. 12, 2015 /PRNewswire/ ... Broad Institute of MIT and Harvard for use ... chemical discovery information management tools. The partnership will ... share both biological and chemical research information internally ... tools will be used for managing the Institute,s ...
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
Breaking Biology News(10 mins):